FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802665535> ?p ?o ?g. }

• W2802665535 abstract "684 Background: While carcinoembryonic antigen (CEA) as a tumor marker is frequently used in the management of colorectal adenocarcinoma, its clinical utility in squamous cell carcinoma of the anus (SCCA) has never been reported. Indeed, no tumor markers have been validated for monitoring tumor burden in the course of any HPV-associated malignancy like SCCA. We hypothesized that CEA levels might be preferentially elevated in patients with metastatic SCCA. Methods: Charts from 212 patients with SCCA were reviewed under an IRB-approved protocol for correlations between CEA levels and corresponding oncologic status. Clinical status was categorized as newly diagnosed non-metastatic (D), after chemoradiation with no evident remnant disease (N), recurrent/resectable SCCA (R), locally advanced/unresectable SCCA (U), metastatic SCCA to lymph nodes only (M-LN), or metastatic SCCA to visceral organs (M-V). Mean CEA levels were compared between subgroups via student t-tests, and frequencies of elevated CEA were compared via Chi-squared analyses. Results: 118 SCCA patients had metastatic disease (98 M-V, 19 M-LN). Mean CEA levels by clinical status were 5.4 (D), 2.0 (N), 2.3 (R), 4.6 (U), 6.0 (M-LN), and 22.2 (M-V), with a higher (statistically insignificant) mean CEA level in the M-V relative to other populations. However, patients with visceral metastases were more likely to have an elevated CEA at presentation (40.4%) relative to patients with newly diagnosed, non-metastatic SCCA (17.6%, p = .07) or recurrent SCCA (11.1%, p = .02). For patients with metastatic SCCA, a significant association existed between change in CEA and corresponding change in radiographic tumor dimensions (OR 24, p < 0.0001). Conclusions: Trends in CEA correlate with dynamic changes in tumor burden for patients with metastatic SCCA, and patients with metastatic SCCA were more likely to have an elevated CEA. Given that immune checkpoint blockade agents like nivolumab have proven benefit for metastatic SCCA, these data provide rationale for use of newer generation immunotherapeutic approaches like CEA-T cell bispecific antibodies, which target CEA-expressing tumors, in clinical trials for patients with metastatic SCCA." @default.
• W2802665535 created "2018-05-17" @default.
• W2802665535 creator A5008945537 @default.
• W2802665535 creator A5009132832 @default.
• W2802665535 creator A5010668711 @default.
• W2802665535 creator A5011546832 @default.
• W2802665535 creator A5022898855 @default.
• W2802665535 creator A5026500137 @default.
• W2802665535 creator A5034037126 @default.
• W2802665535 creator A5035371911 @default.
• W2802665535 creator A5050429899 @default.
• W2802665535 creator A5056376861 @default.
• W2802665535 creator A5065553888 @default.
• W2802665535 creator A5079075847 @default.
• W2802665535 creator A5080692116 @default.
• W2802665535 creator A5082076897 @default.
• W2802665535 creator A5082668053 @default.
• W2802665535 creator A5087201995 @default.
• W2802665535 creator A5088389768 @default.
• W2802665535 creator A5089703059 @default.
• W2802665535 date "2018-02-01" @default.
• W2802665535 modified "2023-09-24" @default.
• W2802665535 title "CEA as a pharmacodynamic biomarker for metastatic anal cancer." @default.
• W2802665535 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.684" @default.
• W2802665535 hasPublicationYear "2018" @default.
• W2802665535 type Work @default.
• W2802665535 sameAs 2802665535 @default.
• W2802665535 citedByCount "1" @default.
• W2802665535 countsByYear W28026655352019 @default.
• W2802665535 crossrefType "journal-article" @default.
• W2802665535 hasAuthorship W2802665535A5008945537 @default.
• W2802665535 hasAuthorship W2802665535A5009132832 @default.
• W2802665535 hasAuthorship W2802665535A5010668711 @default.
• W2802665535 hasAuthorship W2802665535A5011546832 @default.
• W2802665535 hasAuthorship W2802665535A5022898855 @default.
• W2802665535 hasAuthorship W2802665535A5026500137 @default.
• W2802665535 hasAuthorship W2802665535A5034037126 @default.
• W2802665535 hasAuthorship W2802665535A5035371911 @default.
• W2802665535 hasAuthorship W2802665535A5050429899 @default.
• W2802665535 hasAuthorship W2802665535A5056376861 @default.
• W2802665535 hasAuthorship W2802665535A5065553888 @default.
• W2802665535 hasAuthorship W2802665535A5079075847 @default.
• W2802665535 hasAuthorship W2802665535A5080692116 @default.
• W2802665535 hasAuthorship W2802665535A5082076897 @default.
• W2802665535 hasAuthorship W2802665535A5082668053 @default.
• W2802665535 hasAuthorship W2802665535A5087201995 @default.
• W2802665535 hasAuthorship W2802665535A5088389768 @default.
• W2802665535 hasAuthorship W2802665535A5089703059 @default.
• W2802665535 hasConcept C111113717 @default.
• W2802665535 hasConcept C112705442 @default.
• W2802665535 hasConcept C121608353 @default.
• W2802665535 hasConcept C126322002 @default.
• W2802665535 hasConcept C143998085 @default.
• W2802665535 hasConcept C185592680 @default.
• W2802665535 hasConcept C2779840525 @default.
• W2802665535 hasConcept C2781197716 @default.
• W2802665535 hasConcept C502942594 @default.
• W2802665535 hasConcept C526805850 @default.
• W2802665535 hasConcept C55493867 @default.
• W2802665535 hasConcept C71924100 @default.
• W2802665535 hasConceptScore W2802665535C111113717 @default.
• W2802665535 hasConceptScore W2802665535C112705442 @default.
• W2802665535 hasConceptScore W2802665535C121608353 @default.
• W2802665535 hasConceptScore W2802665535C126322002 @default.
• W2802665535 hasConceptScore W2802665535C143998085 @default.
• W2802665535 hasConceptScore W2802665535C185592680 @default.
• W2802665535 hasConceptScore W2802665535C2779840525 @default.
• W2802665535 hasConceptScore W2802665535C2781197716 @default.
• W2802665535 hasConceptScore W2802665535C502942594 @default.
• W2802665535 hasConceptScore W2802665535C526805850 @default.
• W2802665535 hasConceptScore W2802665535C55493867 @default.
• W2802665535 hasConceptScore W2802665535C71924100 @default.
• W2802665535 hasLocation W28026655351 @default.
• W2802665535 hasOpenAccess W2802665535 @default.
• W2802665535 hasPrimaryLocation W28026655351 @default.
• W2802665535 hasRelatedWork W1584168505 @default.
• W2802665535 hasRelatedWork W2032940644 @default.
• W2802665535 hasRelatedWork W2040479834 @default.
• W2802665535 hasRelatedWork W2281559481 @default.
• W2802665535 hasRelatedWork W2376706697 @default.
• W2802665535 hasRelatedWork W2396902412 @default.
• W2802665535 hasRelatedWork W2397964621 @default.
• W2802665535 hasRelatedWork W2410110139 @default.
• W2802665535 hasRelatedWork W2410142697 @default.
• W2802665535 hasRelatedWork W2416465006 @default.
• W2802665535 hasRelatedWork W2418090899 @default.
• W2802665535 hasRelatedWork W2421653546 @default.
• W2802665535 hasRelatedWork W2425759249 @default.
• W2802665535 hasRelatedWork W2460571087 @default.
• W2802665535 hasRelatedWork W2467121783 @default.
• W2802665535 hasRelatedWork W2472189670 @default.
• W2802665535 hasRelatedWork W2737316224 @default.
• W2802665535 hasRelatedWork W2782974984 @default.
• W2802665535 hasRelatedWork W2890734237 @default.
• W2802665535 hasRelatedWork W398810889 @default.
• W2802665535 isParatext "false" @default.
• W2802665535 isRetracted "false" @default.
• W2802665535 magId "2802665535" @default.
• W2802665535 workType "article" @default.